You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the XARELTO (rivaroxaban) Drug Profile, 2024 PDF Report in the Report Store ~

Drug Sales Trends for xarelto


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for xarelto (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $977,284,291
INSIDE ANOTHER STORE $1,921,645,625
[disabled in preview] $3,358,405,780
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 1,068,557
INSIDE ANOTHER STORE 2,210,514
[disabled in preview] 4,987,818
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $403,465,345
MEDICARE $3,389,531,156
[disabled in preview] $2,464,339,196
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for xarelto
Drug Units Sold Trends for xarelto

Annual Sales Revenues and Units Sold for xarelto

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
XARELTO ⤷  Subscribe ⤷  Subscribe 2021
XARELTO ⤷  Subscribe ⤷  Subscribe 2020
XARELTO ⤷  Subscribe ⤷  Subscribe 2019
XARELTO ⤷  Subscribe ⤷  Subscribe 2018
XARELTO ⤷  Subscribe ⤷  Subscribe 2017
XARELTO ⤷  Subscribe ⤷  Subscribe 2016
>Drug Name >Revenues (USD) >Units >Year

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.